02085nas 2200565-a 450 991024705490332120200728071406.61673-7520(DE-599)ZDB2388869-6(OCoLC)213488154(CKB)1000000000278579(CONSER)--2008262107(EXLCZ)99100000000027857920080320b20072011 --- -engur|||||||||||txtrdacontentcrdamediacrrdacarrierFrontiers of environmental science & engineering in China[Beijing] :Higher Education Press ;[Berlin] :Springer,[2007-2011]1 online resourceRefereed/Peer-reviewed"Selected publications from Chinese universities."1673-7415 Frontiers of environmental science and engineering in ChinaFront. Environ. Sci. Engin. ChinaFRONTIERS OF ENVIRONMENTAL SCIENCE AND ENGINEERING IN CHINAFRONT. ENVIRON. SCI. ENG. CHINFRONT ENVIRON SCI ENEnvironmental sciencesResearchChinaPeriodicalsEnvironmental engineeringResearchChinaPeriodicalsGreen technologyChinaPeriodicalsEnvironmental engineeringResearchfast(OCoLC)fst00912962Environmental sciencesResearchfast(OCoLC)fst00913504Green technologyfast(OCoLC)fst00947645ChinafastPeriodicals.fastElectronic journals.Environmental SciencesEnvironmental sciencesResearchEnvironmental engineeringResearchGreen technologyEnvironmental engineeringResearch.Environmental sciencesResearch.Green technology.JOURNAL9910247054903321Frontiers of environmental science & engineering in China1981549UNINA02193nam0 2200433 i 450 VAN011494420220314084505.66N978-3-319-41945-920180216d2016 |0itac50 baengCH|||| |||||Mathematical analysis, probability and applications–plenary lecturesISAAC 2015, Macau, ChinaTao Qian, Luigi G. Rodino editors[Cham]Springer2016VII, 336 p.ill.24 cm001VAN01025742001 Springer proceedings in mathematics & statistics210 Berlin [etc.]Springer177VAN0242843Mathematical analysis, probability and applications : Plenary lectures215597560GxxStochastic processes [MSC 2020]VANC020000MF46ExxLinear function spaces and their duals [MSC 2020]VANC020090MF35QxxPartial differential equations of mathematical physics and other areas of application [MSC 2020]VANC022881MFFunctional analysis and function spacesKW:KOperator theory and Fourier analysisKW:KPartial differential equationsKW:KPartial differential equations of mathematical physicsKW:KProbability and stochastic processesKW:KSeveral complex variables and analytic spacesKW:KCHChamVANL001889QianTaoVANV088948RodinoLuigi G.VANV041871International ISAAC Congress10.2015Macai, ChinaVANV088949Springer <editore>VANV108073650ITSOL20240614RICAhttp://dx.doi.org/10.1007/978-3-319-41945-9E-book – Accesso al full-text attraverso riconoscimento IP di Ateneo, proxy e/o ShibbolethBIBLIOTECA CENTRO DI SERVIZIO SBAVAN15NVAN0114944BIBLIOTECA CENTRO DI SERVIZIO SBA15CONS SBA EBOOK 2348 15EB 2348 20180216 Mathematical Analysis, Probability and Applications – Plenary Lectures2155975UNICAMPANIA04056nam 2200457z- 450 991026114190332120210211(CKB)4100000002484673(oapen)https://directory.doabooks.org/handle/20.500.12854/56127(oapen)doab56127(EXLCZ)99410000000248467320202102d2017 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierPhage Therapy: Past; Present and FutureFrontiers Media SA20171 online resource (392 p.)Frontiers Research Topics2-88945-251-4 Historically, the first observation of a transmissible lytic agent that is specifically active against a bacterium (Bacillus anthracis) was by a Russian microbiologist Nikolay Gamaleya in 1898. At that time, however, it was too early to make a connection to another discovery made by Dmitri Ivanovsky in 1892 and Martinus Beijerinck in 1898 on a non-bacterial pathogen infecting tobacco plants. Thus the viral world was discovered in two of the three domains of life, and our current understanding is that viruses represent the most abundant biological entities on the planet. The potential of bacteriophages for infection treatment have been recognized after the discoveries by Frederick Twort and Felix d'Hérelle in 1915 and 1917. Subsequent phage therapy developments, however, have been overshadowed by the remarkable success of antibiotics in infection control and treatment, and phage therapy research and development persisted mostly in the former Soviet Union countries, Russia and Georgia, as well as in France and Poland. The dramatic rise of antibiotic resistance and especially of multi-drug resistance among human and animal bacterial pathogens, however, challenged the position of antibiotics as a single most important pillar for infection control and treatment. Thus there is a renewed interest in phage therapy as a possible additive/alternative therapy, especially for the infections that resist routine antibiotic treatment. The basis for the revival of phage therapy is affected by a number of issues that need to be resolved before it can enter the arena, which is traditionally reserved for antibiotics. Probably the most important is the regulatory issue: How should phage therapy be regulated? Similarly to drugs? Then the co-evolving nature of phage-bacterial host relationship will be a major hurdle for the production of consistent phage formulae. Or should we resort to the phage products such as lysins and the corresponding engineered versions in order to have accurate and consistent delivery doses? We still have very limited knowledge about the pharmacodynamics of phage therapy. More data, obtained in animal models, are necessary to evaluate the phage therapy efficiency compared, for example, to antibiotics. Another aspect is the safety of phage therapy. How do phages interact with the immune system and to what costs, or benefits? What are the risks, in the course of phage therapy, of transduction of undesirable properties such as virulence or antibiotic resistance genes? How frequent is the development of bacterial host resistance during phage therapy? Understanding these and many other aspects of phage therapy, basic and applied, is the main subject of this Topic.Phage TherapyMicrobiology (non-medical)bicsscbacterial infection treatmentbacteriophage therapybiocontrolbiofilmsimmunologylysinsregulatory issuesMicrobiology (non-medical)Abedon Stephen Tauth1239822Garcia PilarauthAminov RustamauthMullany Peter1959-authBOOK9910261141903321Phage Therapy: Past; Present and Future3855566UNINA